Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares GlobeNewswire - Mon Dec 1, 9:37PM CST

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 151.27 (-0.34%)
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares GlobeNewswire - Mon Dec 1, 3:20PM CST

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics...

BLTE : 151.27 (-0.34%)
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease GlobeNewswire - Mon Dec 1, 5:00AM CST

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033 Tinlarebant met...

BLTE : 151.27 (-0.34%)
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire - Mon Nov 10, 7:00AM CST

Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placement with potential...

BLTE : 151.27 (-0.34%)
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results GlobeNewswire - Mon Nov 3, 7:00AM CST

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases...

BLTE : 151.27 (-0.34%)
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant GlobeNewswire - Sun Nov 2, 8:00AM CST

MHRA response is based on the Phase 3 DRAGON interim analysis results  Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE),...

BLTE : 151.27 (-0.34%)
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference GlobeNewswire - Wed Oct 29, 7:00AM CDT

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...

BLTE : 151.27 (-0.34%)
H.C. Wainwright Remains a Buy on Belite Bio, Inc. ADR (BLTE) Tipranks - Fri Oct 17, 8:18AM CDT

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR, with a price target of $98.00. The company’s shares closed yesterday at $81.26.Elevate Your Investing...

BLTE : 151.27 (-0.34%)
Leerink Partners Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE) Tipranks - Thu Oct 16, 2:10PM CDT

Leerink Partners analyst Marc Goodman reiterated a Buy rating on Belite Bio, Inc. ADR today. The company’s shares opened today at $80.00.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

BLTE : 151.27 (-0.34%)
Belite Bio to Participate in the 2025 Maxim Growth Summit GlobeNewswire - Thu Oct 16, 7:00AM CDT

SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...

BLTE : 151.27 (-0.34%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot